Worth reading
62In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
500000
DollarWording
Conditional
How definitive the wording is.Agreements reached under this partnership
Business Alliances4586Medrx Co.,Ltd.
Alliance partnerTerrain Pharmaceuticals, Inc.
Details of the alliance
- 1
Granting exclusive U.S. distribution rights for Bondlido, a lidocaine patch
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
About the partner
Business DescriptionSpecialty pharmaceuticals
LocationReno, Nevada, U.S.
Share capitalNot disclosed at the partner’s request
Net SalesNot disclosed at the partner’s request
Operating profitNot disclosed at the partner’s request
Impact on Business Performance
A one-time contractual payment of $500,000 is expected to be received in the fiscal year ending December 2026. In addition, メドレックス will supply Bondlido exclusively to Terrain and receive royalty income based on annual sales.
Date of board resolution15 May 2026Contract Date15 May 2026 (legally binding term sheet)Alliance start dateLaunch scheduled for the second half of 2026
| Item | Details |
|---|---|
| Name of alliance partner | Terrain Pharmaceuticals, Inc. |
| Alliance partner's business activities | Specialty pharmaceuticals |
| Alliance partner's location | Reno, Nevada, U.S. |
| Alliance partner's capital | Not disclosed at the partner’s request |
| Alliance partner's net sales | Not disclosed at the partner’s request |
| Alliance partner's operating income | Not disclosed at the partner’s request |
| Type of alliance | Business Alliances |
| Details of the alliance | Granting exclusive U.S. distribution rights for Bondlido, a lidocaine patch |
| Date of board resolution | 15 May 2026 |
| Contract Date | 15 May 2026 (legally binding term sheet) |
| Alliance start date | Launch scheduled for the second half of 2026 |
| Impact on Business Performance | A one-time contractual payment of $500,000 is expected to be received in the fiscal year ending December 2026. In addition, メドレックス will supply Bondlido exclusively to Terrain and receive royalty income based on annual sales. |
Items this document does not state (11)
Number of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyShare Acquisition Date and Payment DateChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To monetize Bondlido, a lidocaine patch, in the U.S. market.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.